Chugai Pharmaceutical Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Chugai Pharmaceutical stock has a consensus rating of "Buy" and an average price target of ¥9,183. The average 1-year stock price forecast is 44.35% higher than the current stock price, while the lowest is ¥7,100 (+11.60%) and the highest is ¥13,300 (+109.05%).

Price Target: ¥9,183 (+44.35%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	¥7,100	¥9,183	¥8,950	¥13,300
Change	+11.60%	+44.35%	+40.68%	+109.05%

Analyst Ratings

The average analyst rating for Chugai Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Apr '26	May '26	Jun '26	Jul '26	Aug '26	Sep '26
Strong Buy	5	5	6	6	5	5
Buy	4	4	4	5	5	5
Hold	6	6	5	4	5	5
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	15	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst SBI Securities No rating	SBI Securities	Buy Maintains ¥9,500	Buy	Maintains	¥9,500	+49.32%	Sep 9, 2026
Unknown Analyst Nomura No rating	Nomura	Hold Maintains ¥8,000 → ¥7,600	Hold	Maintains	¥8,000 → ¥7,600	+19.46%	Sep 1, 2026
Unknown Analyst Mizuho Securities No rating	Mizuho Securities	Hold Maintains ¥8,250 → ¥7,100	Hold	Maintains	¥8,250 → ¥7,100	+11.60%	Aug 19, 2026
Unknown Analyst Bank of America Securities No rating	Bank of America Securities	Hold Maintains ¥8,800 → ¥7,500	Hold	Maintains	¥8,800 → ¥7,500	+17.89%	Aug 14, 2026
Unknown Analyst UBS No rating	UBS	Hold Downgrades ¥9,800 → ¥7,200	Hold	Downgrades	¥9,800 → ¥7,200	+13.17%	Aug 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.38T

from 1.26T

9.91%

from 1.26T

Revenue Next Year

1.53T

from 1.38T

10.36%

from 1.38T

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	999.76B	1.26T	1.11T	1.17T	1.26T	1.38T
Revenue Growth	27.04%	26.03%	-11.79%	5.33%	7.46%	9.91%
Gross Profit	661.61B	783.70B	698.06B	831.20B	894.25B	1.00T
Gross Margin	66.18%	62.20%	62.81%	71.01%	71.09%	72.53%
Operating Income	421.90B	533.31B	439.17B	542.00B	598.83B	691.50B
Net Income	303.00B	374.43B	325.47B	387.32B	434.01B	504.47B
Dividend / Share	76.00	78.00	80.00	98.00	122.00	134.85
Dividend Growth	38.18%	2.63%	2.56%	22.50%	24.49%	10.53%
Free Cash Flow	-	-	-	-	185.01B	441.83B
No. Analysts	-	-	-	-	-	14

Financial currency is JPY.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	1.4T
Avg	1.4T
Low	1.4T

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	12.3%
Avg	9.9%
Low	7.9%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

Chart

EPS Growth	2027	2028
High	-
Avg	-
Low	-